Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Plus Celecoxib in dMMR/MSI-H Locally Advanced Colorectal Cancer (PICC-3)
NCT06903858Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2025
- Primary completion
- Apr 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, celecoxib oral solution in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Started Jun 2025; status: recruiting.
02
Drugs
toripalimabcelecoxib oral solution
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06903858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903858.